会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明公开
    • SMALL MOLECULES FOR INHIBITING MALE FERTILITY
    • KLEINMOLEKÜLEZUR HEMMUNG DERMÄNNLICHENFRUCHTBARKEIT
    • EP3116861A1
    • 2017-01-18
    • EP15761799.4
    • 2015-03-13
    • The University of North Carolina at Chapel Hill
    • O'RAND, Michael
    • C07D251/52C07D253/07C07D253/075C07D487/04C07D498/04A61K31/53A61P15/16
    • C07D251/52A61K31/53C07D253/07C07D253/075C07D487/04C07D498/04
    • Compounds suitable for use in providing male contraception, an assay method for identifying such compounds, and methods of providing contraception using the compounds, are provided. In one embodiment, the compounds described herein mimic the binding of anti-EPPIN antibodies to EPPIN, and thus inhibit the forward motility of sperm in humans and other primates. In another embodiment, the compounds described herein inhibit or enhance EPPIN-semenogelin binding, and inhibit forward motility of sperm. The assays described herein identify compounds which inhibit sperm motility, and can be carried out in a high throughput manner, using labeled recombinant EPPIN and semenogelin. The compounds can be used in oral or transdermal compositions to temporarily and reversibly inhibit male fertility. They can also be used in addition to, or in place of, spermicides in spermicidal compositions, such as those used in conjunction with condoms, diaphragms, and spermicidal jellies.
    • 提供了适用于提供男性避孕的化合物,用于鉴定这些化合物的测定方法以及使用该化合物提供避孕方法。 在一个实施方案中,本文所述的化合物模拟抗EPPIN抗体与EPPIN的结合,并因此抑制精子在人和其他灵长类动物中的向前运动。 在另一个实施方案中,本文所述的化合物抑制或增强EPPIN-精液素结合,并抑制精子的向前运动。 本文描述的测定法使用标记的重组EPPIN和精液蛋白来鉴定抑制精子活力的化合物,并且可以以高通量的方式进行。 这些化合物可用于口服或透皮组合物中以暂时和可逆地抑制雄性生育力。 除了杀精组合物中的杀精剂外,还可以使用它们,例如与避孕套,隔膜和杀精胶冻结合使用的杀精剂。
    • 10. 发明公开
    • MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
    • 前列腺素(PGI2)受体的调节剂可用于治疗与其有关的疾病
    • EP2370413A1
    • 2011-10-05
    • EP09775380.0
    • 2009-12-07
    • Arena Pharmaceuticals, Inc.
    • TRAN, Thuy-AnhHAYASHI, RenaIBARRA, Jason B.ULLMAN, BrettZOU, Ning
    • C07D237/14C07D401/04C07D403/04C07D409/04C07D253/07A61K31/50A61K31/501A61K31/53A61P11/08
    • C07D237/14C07D253/07C07D401/04C07D403/04C07D409/04
    • Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).
    • 式Ia的环己烷衍生物及其调节PGI 2受体活性的药物组合物。 本发明的化合物及其药物组合物涉及可用于治疗肺动脉高压(PAH)和相关病症的方法; 血小板聚集; 冠状动脉疾病; 心肌梗塞; 短暂性脑缺血发作; 心绞痛; 行程; 缺血再灌注损伤; 再狭窄; 心房颤动; 血管成形术或冠状动脉旁路手术中的血块形成个体或患有心房纤颤的个体; 动脉粥样硬化; 动脉粥样硬化; 哮喘或其症状; 糖尿病相关病症如糖尿病周围神经病变,糖尿病肾病或糖尿病视网膜病变; 青光眼或眼内压异常的其他疾病; 高血压; 炎; 银屑病; 银屑病关节炎; 类风湿关节炎; 克罗恩病; 移植排斥; 多发性硬化症; 系统性红斑狼疮(SLE); 溃疡性结肠炎; 缺血再灌注损伤; 再狭窄; 动脉粥样硬化; 粉刺; 1型糖尿病; 2型糖尿病; 败血症; 和慢性阻塞性肺病(COPD)。